The role of cytokines in polycystic ovarian syndrome

References

• Ascunion M, Calvo RM, San Milan JL, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metabol 2000;85:2434–8
   Google Scholar
• Stein F, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181–91
   Google Scholar
• Glintborg D, Adersen M. An update on the pathogenesis, inflammation and metabolism in hirsutism and polycystic ovary syndrome. Gynecol Endocrinol 2010;26:281–96
   PubMed Web of Science ®Google Scholar
• The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25
   Web of Science ®Google Scholar
• Repaci A, Gambineri A, Pasquali R. The role of low-grade inflammation in the polycystic ovary syndrome. Mol Cell Endocrinol 2011;335:30–41
   PubMed Web of Science ®Google Scholar
• Cibula D, Cifkova R, Fanta M, et al. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in peri-menopausal women with a history of the polycystic ovary syndrome. Human Reprod 2000;15:785–9
   PubMed Web of Science ®Google Scholar
• Legro RS. Diabetes prevalence and risk factors in polycystic ovary syndrome. Curr Opin Endocrinol Diabetes 2002;9:451–8
   Google Scholar
• Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol 2000;52:595–600
   PubMed Web of Science ®Google Scholar
• González F. Inflammation in polycystic ovary syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids 2012;77:300–5
   PubMed Web of Science ®Google Scholar
• González F, Rote NS, Minium J, Kirwan JP. Increased activation of nuclear factor κB triggers inflammation and insulin resistance in polycystic ovary syndrome. J Clin Endocrinol Metabol 2006;91:1508–12
   PubMed Web of Science ®Google Scholar
• Xiong YL, Liang XY, Yang X, et al. Low-grade chronic inflammation in the peripheral blood and ovaries of women with polycystic ovarian syndrome. Eur J Obstet Gynecol Reprod Biol 2011;159:148–50
   PubMed Web of Science ®Google Scholar
• Amato G, Conte M, Mazziotti G, et al. Serum and follicular fluid cytokines in polycystic ovary syndrome during stimulated cycles. Obstet Gynecol 2003;101:1177–82
   PubMed Web of Science ®Google Scholar
• Fulghesu AM, Sanna F, Uda, S, et al. IL-6 serum levels and production is related to an altered immune response in polycystic ovary syndrome girls with insulin resistance. Mediators Inflammat 2011;2011:389317; doi:10.1155/2011/389317; Epub 2011 Mar 20
   PubMed Web of Science ®Google Scholar
• Samy N, Hashim M, Sayed M, Said M. Clinical significance of inflammatory markers in polycystic ovary syndrome: their relationship to insulin resistance and body mass index. Dis Marker 2009; 26:163–70
   PubMed Web of Science ®Google Scholar
• Yang Y, Qiao J, Li R, Li MZ. Is interleukin-18 associated with polycystic ovary syndrome? Reprod Biol Endocrinol 2011;9:7–11
   PubMed Web of Science ®Google Scholar
• Kelly CCJ, Lyall H, Petrie JR, et al. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metabol 2001;86:2453–5
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141–6
   PubMed Web of Science ®Google Scholar
• Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 2004;59:141–154
   PubMed Web of Science ®Google Scholar
• Kirchengast S, Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Human Reprod 2001;16:1255–60
   PubMed Web of Science ®Google Scholar
• Horejsi R, Möller R, Racki S, et al. Android subcutaneous tissue adipose topography in lean and obese women suffering from PCOS: comparison with type 2 diabetic women. Am J Phys Anthropol 2004;124:275–81
   PubMed Web of Science ®Google Scholar
• Sathyapalan T, Atkin SL. Mediators of inflammation in polycystic ovary syndrome in relation to adiposity. Mediators Inflammat 2010;2010:758656; doi:10.1155/2010/758656; Epub 2010 Apr 8
   PubMed Web of Science ®Google Scholar
• Moshage HJ, Roelofs HMJ, van Pelt JF, et al. The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes. Biochem Biophys Res Commun 1988;155:112–7
   PubMed Web of Science ®Google Scholar
• Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003; 107:671–4
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale HF, Luque-Ramírez M, González F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril 2011;95:1048–58. e2
   PubMed Web of Science ®Google Scholar
• Cortón M, Botella-Carretero JI, Benguría A, et al. Differential gene expression profile in omental adipose tissue in women with polycystic ovary syndrome. J Clin Endocrinol Metabol 2007;92:328–37
   PubMed Web of Science ®Google Scholar
• González F, Minium J, Rote NS, Kiwan JP. Hyperlycemia alters tumor necrosis factor-α release from mononuclear cells in women with polycystic ovary syndrome. J Clin Endocrinol Metabol 2005;90:5336–42
   PubMed Web of Science ®Google Scholar
• González F, Rote NS, Minium J, Kirwan JP. In vitro evidence that hyperglycemia stimulates tumor necrosis factor-α release in obese women with polycystic ovary syndrome. J Endocrinol 2006;188:521–9
   PubMed Web of Science ®Google Scholar
• Spaczynski RZ, Arici A, Duleba AJ. Tumor necrosis factor-α stimulates proliferation of rat ovarian theca-interstitial cells. Biol Reprod 1999;61:993–8
   PubMed Web of Science ®Google Scholar
• Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metabol 1980;50:113–6
   PubMed Web of Science ®Google Scholar
• Bhatia V. Insulin resistance and inflammation in polycystic ovarian syndrome – newer concepts and role of insulin sensitizers. Curr Med Literat Gynecol Obstet 2006;11:49–57
   Google Scholar
• Barber TM, McCarthy MI, Wass JAH, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol 2006;65:137–45
   PubMed Web of Science ®Google Scholar
• O’Rourke RW, Kay T, Lyle EA, et al. Alterations in peripheral blood lymphocyte cytokine expression in obesity. Clin Exp Immunol 2006;146:39–46
   Google Scholar
• ACOG Committee on Practice Bulletins – Gynecology. ACOG practice bulletin no. 108: polycystic ovary syndrome. Obstet Gynecol 2009;114:936–49
   Google Scholar
• Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol 1992;36:150–11
   Google Scholar
• Diamanti-Kandarakis E, Paterakis T, Alexandraki K, et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Human Reprod 2006;21:1426–32
   PubMed Web of Science ®Google Scholar
• Morin-Papunen L, Rautio K, Ruokonen A, et al. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metabol 2003;88:4649–54
   PubMed Web of Science ®Google Scholar
• Ghazeeri G, Kutteh WH, Bryer-Ash M, et al. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 2003;79:562–6
   PubMed Web of Science ®Google Scholar
• Sepilian V, Nagamani M. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. J Clin Endocrinol Metabol 2005;90:60–5
   PubMed Web of Science ®Google Scholar
• Dhindsa G, Bhatia R, Dhindsa M, Bhatia V. Insulin resistance, insulin sensitization and inflammation in polycystic ovarian syndrome. J Postgrad Med 2004;50:140–4
   PubMedGoogle Scholar
• Duleba AJ, Banaszewska B, Spaczynski RZ, Pawelczyk L. Simvastatin improves biochemical parameters of polycystic ovary syndrome: results of a prospective randomized trial. Fertil Steril 2006; 85:996–1001
   PubMed Web of Science ®Google Scholar
• Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL. The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. J Clin Endocrinol Metabol 2009;94:103–8
   PubMed Web of Science ®Google Scholar
• Banaszewska B, Pawelczyk L, Spaczynski RZ,Duleba AJ. Comparison of simvastatin and metformin treatment of polycystic ovary syndrome: prospective randomized trial. J Clin Endocrinol Metabol 2009;94:4938–45
   PubMed Web of Science ®Google Scholar
• Tait AS, Butts CL, Sternberg EM. The role of glucocorticoids and progestins in inflammatory, autoimmune and infectious disease. J Leukocyte Biol 2008; 84:924–31
   PubMed Web of Science ®Google Scholar
• Ansar Ahmed S, Penhale WJ, Talal N. Sex hormones, immune responses, and autoimmune diseases. Mechanisms of sex hormone action. Am J Pathol 1985;121:531–51
   PubMed Web of Science ®Google Scholar
• Butts CL, Shukair SA, Duncan KM, et al. Progesterone inhibits mature rat dendritic cells in a receptor-mediated fashion. Int Immunol 2007;19:287–96
   PubMedGoogle Scholar
• Banaszewska B, Spaczynski RZ, Ozegowska K, Pawelczyk L. The influence of low-dose oral contraceptive pill on clinical and metabolic parameters in young women with polycystic ovary syndrome. Ginekolog Polska 2011;82:430–5
   PubMed Web of Science ®Google Scholar